Acun Ceyda, Tomac Nazan, Ermis Bahri, Onk Gulzade
Department of Pediatrics, Karaelmas University, Faculty Of Medicine, Zonguldak, Turkey.
Allergy Asthma Proc. 2005 May-Jun;26(3):204-6.
In asthmatic children inhaled corticosteroids are widely used. However, there are some concerns about the systemic adverse effects of these drugs, especially in the growing child. We performed this prospective study in order to compare the effects of 400 microg/day of budesonide (BUD) and 250 microg/day of fluticasone propionate (FP) on growth in prepubertal (aged 4-11.5 years), moderate persisting asthmatic children. One hundred patients (51 boys and 49 girls), who were randomized into two groups, were recruited for the study. The first group was treated with BUD, 2X 200 microg/day, and the second group was treated with FP, 2X 125 microg/day, by using a medium-size volume-spacer metered-dose inhaler. Growth in children with asthma who were treated by inhaled corticosteroids was calculated by growth velocity over a 12-month period. Comparisons between treatment groups were calculated by t-test and chi-square test. There were no significant differences between BUD and FP groups for sex, age, first height, and growth velocity. Moderate persisting, prepubertal asthmatic children treated with 250 microg/day of FP appeared to have no different linear growth than those children who received 400 microg/day of BUD.
在哮喘儿童中，吸入性糖皮质激素被广泛使用。然而，人们对这些药物的全身不良反应存在一些担忧，尤其是在正在成长的儿童中。我们进行了这项前瞻性研究，以比较每天400微克布地奈德（BUD）和每天250微克丙酸氟替卡松（FP）对青春期前（4至11.5岁）中度持续性哮喘儿童生长的影响。招募了100名患者（51名男孩和49名女孩），随机分为两组进行研究。第一组使用中等容量储雾罐定量吸入器，每天2次，每次200微克布地奈德进行治疗，第二组每天2次，每次125微克丙酸氟替卡松进行治疗。通过计算12个月期间的生长速度来评估接受吸入性糖皮质激素治疗的哮喘儿童的生长情况。治疗组之间的比较采用t检验和卡方检验。布地奈德组和丙酸氟替卡松组在性别、年龄、初始身高和生长速度方面无显著差异。接受每天250微克丙酸氟替卡松治疗的中度持续性青春期前哮喘儿童的线性生长与接受每天400微克布地奈德治疗的儿童似乎没有差异。
